1. Home
  2. PRAX vs CFR Comparison

PRAX vs CFR Comparison

Compare PRAX & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$289.43

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Cullen/Frost Bankers Inc.

CFR

Cullen/Frost Bankers Inc.

HOLD

Current Price

$129.79

Market Cap

8.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
CFR
Founded
2015
1868
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
8.1B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PRAX
CFR
Price
$289.43
$129.79
Analyst Decision
Strong Buy
Hold
Analyst Count
15
13
Target Price
$572.13
$143.08
AVG Volume (30 Days)
308.0K
520.5K
Earning Date
05-01-2026
04-30-2026
Dividend Yield
N/A
3.09%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$9.72
Revenue Next Year
$6,395.88
$4.70
P/E Ratio
N/A
$14.55
Revenue Growth
N/A
N/A
52 Week Low
$26.70
$100.31
52 Week High
$354.87
$148.97

Technical Indicators

Market Signals
Indicator
PRAX
CFR
Relative Strength Index (RSI) 37.95 26.90
Support Level $266.93 $124.76
Resistance Level $322.32 $129.71
Average True Range (ATR) 16.36 3.29
MACD -4.02 -1.08
Stochastic Oscillator 4.20 3.47

Price Performance

Historical Comparison
PRAX
CFR

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About CFR Cullen/Frost Bankers Inc.

Cullen/Frost is a regional US bank with around $53 billion in assets (as of September 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.

Share on Social Networks: